Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lonaprisan

An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:progesterone receptor antagonist ZK 230211
Code name:ZK 230211
Chemical structure:11β-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17-hydroxy-19-nor-17α-pregna-4,9- dien-3-one
19-norpregna-4,9-dien-3-one, 11-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17- hydroxy-, (11β,17α)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search